223 results about "Body fluid sample" patented technology

To provide a biomarker for clonal hematopoiesis.SOLUTION: The present inventors have found that PYY, LEP, SCN3A, FCGR2A, CYTH3, CD8A, TK1, GBP6, DSC2, GP5, IL17D, CD244, SLC4A1, BGN, APOA4, and MMP7 in a body fluid sample are biomarkers for clonal hematopoiesis.SELECTED DRAWING: None

This invention relates to the field of intelligent information processing technology and discloses an intelligent assessment system for endometrial receptivity based on biosensor data processing. The system acquires signals of multiple types of biomarkers in bodily fluid samples through multi-channel biosensor detection and performs structured preprocessing and quantitative transformation. Based on this, it establishes object-level associations between biosensor data and multi-source information to construct a unified feature data system. Furthermore, it constructs a weighted heterogeneous assessment graph and introduces a manifold stochastic feature modeling mechanism to generate manifold feature data. The manifold features and original features are jointly input into a shared-parameter cyclic Transformer model. Through cyclic inference and consistency constraints, multi-round feature fusion is achieved, outputting the endometrial receptivity assessment result. This invention improves the multi-source data modeling capability and the stability and consistency of the assessment process.

Disclosed are a method for detecting sugi allergen-specific IgE antibodies in a body fluid sample, which can improve the detection value of sugi allergen-specific IgE antibodies, and a kit for use therein. The method comprises the following steps: a removal step for removing non-IgE antibodies such as IgG antibodies from the body fluid sample; a reaction step for contacting the antibody-removed body fluid sample obtained in the removal step with a reaction well on a substrate having a reaction well, thereby forming a complex between the allergen and the allergen-specific IgE antibody; the reaction well comprising a region immobilizing the sugi allergen and regions immobilizing one or more allergens other than the sugi allergen; and a detection step for detecting the complex between the sugi allergen and the sugi allergen-specific IgE antibody obtained in the reaction step.

The invention belongs to the technical field of medical body fluid sample collection, and provides an integrated saliva collection filter which comprises a collection tube, a sponge rod used for collecting saliva is detachably connected in the collection tube through an extrusion part, a filter assembly is arranged at one end of the collection tube, and the liquid inlet end of the filter assembly corresponds to the sponge rod; the flexible liquid storage mechanism comprises a liquid mixing assembly, the liquid mixing assembly is connected with the collecting pipe through a connecting base, a spring microbead one-way valve assembly and a buffer liquid storage assembly are arranged in the connecting base, and the liquid outlet end of the spring microbead one-way valve assembly is communicated with the liquid mixing assembly; the liquid outlet end of the filtering assembly is communicated with the liquid mixing assembly through a spring microbead one-way valve assembly, and an automatic liquid leakage assembly is arranged between the buffer liquid storage assembly and the filtering assembly. Saliva collection, filtration and buffer solution mixing can be completed in one step, and the device is small in size, convenient to store and transport, capable of being integrally discarded after being used, environmentally friendly and efficient.

A rapid diagnostic device for detecting multiple biomarkers in bodily fluid samples, particularly useful for disease screening including breast cancer. The device comprises a housing containing at least one test strip with a sample receiving zone, conjugate pad, and multiple test zones. The test strip utilizes specific materials including Cytiva GF / DVA and Ahlstrom 1667 sample pads, an Ahlstrom 6613 conjugate pad with carboxylated 150 nm gold nanoshell conjugates, and a Sartorius CN140 membrane with precisely positioned test and control zones. The device simultaneously detects multiple biomarkers, such as hCG and CA-15-3, using specific antibodies. Features include a built-in safety lancet, integrated buffer system, and compatibility with various sample types. Results are available within ten minutes, with options for quantitative analysis via a dedicated reader or smartphone application. This multi-biomarker approach potentially improves screening accuracy compared to single-marker tests, offering versatility for detecting various medical conditions.

A system for verifying a sample volume includes a sample reservoir and a volumetric verification device. The sample reservoir defines an inner volume and is configured to receive a volume of bodily fluid. The inner volume of the sample reservoir contains an additive. The volumetric verification device includes a first indicator and a second indicator. The volumetric verification device is configured to selectively engage the sample reservoir to (1) place the first indicator in a first position along a length of the sample reservoir such that the first indicator is substantially aligned with a surface and / or meniscus of the additive and (2) place the second indicator in a second position along the length of the sample reservoir such that the second indicator is substantially aligned with a predetermined fill volume when bodily fluid is transferred to the inner volume.

A computer-implemented method for determining a numerical analyte result value corresponding to the concentration of an analyte in a sample of a subject's body fluid applied to a reagent test area includes: (a) determining the numerical analyte result value based on an image of the reagent test area by using an algorithm that takes into account one or more parameters, each parameter adapted to take two or more values; (b) displaying the numerical analyte result value, and / or the corresponding analyte value range, and / or a corresponding message on a display device; and (c) automatically checking for available updated values ​​for one or more parameters on a remote server before performing step (a), and updating the corresponding parameter value taken into account in step (a) for each available updated value.

The invention discloses a diabetic retinopathy diagnosis and analysis platform based on double body fluids and a method for analyzing a biological fluid sample by using the diabetic retinopathy diagnosis and analysis platform, and relates to the field of biological diagnos.The diabetic retinopathy diagnosis and analysis platform comprises an acquisition and analysis module and a machine learning module, the acquisition and analysis module acquires mass spectrum data of a biological sample through a mass spectrum system for analysis, and the machine learning module analyzes and processes the acquired mass spectrum data of the biological sample, constructs a diabetic retinopathy biomarker panel, and analyzes the diabetic retinopathy biomarker panel to obtain the diabetic retinopathy biomarker. The invention also comprises a method for analyzing a biological fluid sample by using the analysis platform, the biological fluid sample comprises vitreous humor and plasma, and the nanoparticles are used as a matrix of the biological fluid sample for mass spectrum data acquisition. The invention provides a rapid, stable, reliable and high-sensitivity vitreous humor metabonomics detection method and system.

The utility model provides a novel funnel type body fluid sample bottle for collecting and storing body fluid samples, which comprises a bottle body, the top of the bottle body is in threaded connection with a wide-mouth bottle cap, the bottle body comprises a cylindrical bottle body and a conical bottle body, the cylindrical bottle body is connected with the conical bottle body, the cylindrical bottle body is positioned above the conical bottle body, and the conical bottle body is positioned above the conical bottle body. The bottom of the conical flask body is connected with a return pipeline, an annular protrusion is arranged on the inner side of the lower portion of the cylindrical flask body, a supporting frame is arranged below the cylindrical flask body, and the supporting frame is connected or connected to the outer side of the conical flask body in a sleeved mode. The novel funnel-type body fluid sample bottle for collecting and storing the body fluid sample is simple in structure, the wide-mouth bottle above the bottle body is used for collecting body fluid, the lower portion of the bottle body is funnel-shaped, deposition and centrifugation of visible components are facilitated, the bottom of the conical bottle body is connected with the sample outlet through a return pipeline and is controllable and normally closed, operation is simplified, and the bottle is convenient to use. The opportunity that an operator is in contact with the contents to pollute the contents can be avoided, and the concentration of liquid particle components at the lower part is improved.

A composition and method for preserving a wide variety of analyte classes, including but not limited to small molecules, peptides, proteins, nucleic acids, carbohydrates, and lipids, ensuring stability and reproducibility of their compartmental concentration over the time course of storage at room temperature, thus enabling cost-efficient tests and logistics for the analysis of these samples.

This invention relates to the field of medical data and discloses a method for real-time monitoring of the efficacy of traditional Chinese medicine, Mongolian medicine, and Western medicine based on biosensor technology. This method enables real-time monitoring of drug efficacy and personalized medication guidance. The process includes collecting real-time multimodal biosignals from the user's body surface or minimally invasive body fluid samples to obtain raw sensor signals and acquire sensor array output; extracting real-time pharmacokinetic characteristic signals based on a preset pharmacokinetic model and mapping them to efficacy assessment parameters according to drug type; comparing the efficacy assessment parameters with a preset safe and effective concentration range to generate real-time medication status indicators and dosage adjustment prompts. This invention designs quantitative assessment methods for different types of drugs, enabling real-time comparison to generate efficacy status codes and dosage adjustment suggestions. It comprehensively generates a medication guidance report and transmits it in real-time to the user or clinical monitoring end, allowing for immediate adjustment of the medication regimen and ensuring safe and effective medication.

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

The invention relates to the technical field of biomedical detection, in particular to a multi-dimensional tumor marker joint detection device and a using method thereof.The device comprises a sample processing module, a sequencing module, a marker extraction module, a feature fusion and detection module and a result output module, and 6 types of markers such as chromosome copy variation, microsatellite instability and the like are extracted respectively. The method comprises the following steps: collecting a body fluid sample to extract cfDNA, directly constructing a library without special treatment, obtaining effective data through whole genome sequencing, synchronously extracting six types of markers through each module of the device, optimizing an algorithm to adapt to low-depth data, inputting an integrated learning model to output a risk score, and finally outputting related information by a result output module. The method does not need special experimental treatment, realizes low-cost and high-accuracy joint detection, and meets the clinical large-scale screening requirements.

The invention belongs to the technical field of surgical instruments, and provides a body fluid sample collection device for hydrothorax and ascites and a use method thereof. A pretreatment device is arranged between a body fluid bottle and a suction pipeline and comprises a viscosity control part, the viscosity control part is provided with a conical pipe, the inner diameter of the end, close to the suction pipeline, of the conical pipe is smaller than that of the end, away from the suction pipeline, of the conical pipe, and branch pipe openings capable of being opened and closed are formed in the two ends of the conical pipe. The branch pipe openings comprise the first branch pipe opening and the second branch pipe opening, and the first branch pipe opening is closer to the suction pipeline than the second branch pipe opening. The problems that in the hydrothorax and ascites suction process, due to clots such as fibrin of high-viscosity hydrothorax and ascites, a suction pipeline is blocked, and the microscopic examination accuracy is affected are avoided; the problems that before and after the pleural and ascitic fluid needs to be sucked for multiple times and the pleural and ascitic fluid is indwelled and sucked, the pipeline is blocked due to residual clots in the pipeline, and even indwelling and suction instruments need to be replaced are avoided.

A method of detecting an analyte in a body fluid sample using a mobile device having a camera. An image is obtained with the camera of a test field having the body fluid sample applied thereto, causing an optical detection reaction. An algorithm is then performed to determine a potential detection of an optical detection feature and a potential item of intensity information. The potential item of intensity information is weighted with a known item of position probability information. The known item of position probability information is a probability of a potential item of intensity information on the optical detection reaction being a valid item of intensity information. The analyte is detected considering the weighted potential item of intensity information for differentiating a valid from an invalid item of intensity information. A calibration process is then performed in which the known item of position probability information is selected.

The invention relates to a pair of anti-TSH receptor (TSHR) autoantibody-binding fusion proteins consisting of a capture fusion protein and a detection fusion protein, and a method for detecting autoantibodies to the thyroid stimulating hormone receptor (TSHR) in a biological fluid sample, which employs said fusion proteins pair. More specifically, the capture and detection fusion proteins of the pair of the invention comprise an extracellular domain of a human TSHR and a monomeric non-human immunoglobulin Fc domain, or fragment thereof, or a bacterial maltose binding protein (MBP). Also disclosed is a kit for carrying out the method of the invention. In a preferred embodiment, the method of the invention is a sandwich immunoassay.

The present invention relates to a method of screening for osteoarthritis (OA) and rheumatoid arthritis (RA) in a subject suffering from arthritis or suspected of suffering from arthritis and a method of discriminating between OA and rheumatoid arthritis RA comprising determining the level of one or more glycosaminoglycan (GAG) properties according to the invention in a sample of bodily fluid. The invention also provides methods for monitoring OA or RA progression in a subject suffering from arthritis.

Compositions and methods are provided, for preparing DNA libraries for high- throughput sequencing following methylation-sensitive and / or methylation-dependent enzymatic digestion of the DNA. The provided compositions and methods obviate the need to clean-up the DNA sample between the digestion step and subsequent library preparation steps. The provided compositions and methods are particularly advantageous for library preparation from small amounts of DNA, such as cell-free DNA from body fluid samples.

The invention is applicable to the field of in-vitro diagnostic equipment, and discloses a sample analyzer. The sample analyzer comprises a sample introduction device, a sample distribution device, a first visible component detection device, a second visible component detection device and a controller, wherein the first visible component detection device comprises a first microscopic imaging device. The controller is configured to at least output a kinetic analysis result of sperms in the semen sample according to an image obtained by executing a first shooting action on the semen sample by the first microscopic imaging device; and at least outputting a morphological analysis result of at least part of the visible components in the first body fluid sample according to detection data obtained by performing the visible component detection action on the first body fluid sample by the second visible component detection device. According to the invention, one sample analyzer can be used for carrying out visible component analysis on a semen sample and another type of body fluid sample, so that the purchase, use and maintenance cost of the sample analyzer for analyzing the semen sample can be reduced.

The present invention describes a comprehensive system and method for the simultaneous early detection of multiple cancers in a single analysis. The system involves a liquid chromatography-mass spectrometry (LC-MS) instrument coupled with a processor and AI / ML algorithms. The LC-MS instrument analyzes metabolite ions from dried extracts of biological fluid samples and aligns and normalizes the data while minimizing errors. Quality control processes, including neural network models and critical ion monitoring, ensure accurate detection. The system employs an AI / ML process to create two models: a Cancer Detection AI (CDAI) model for identifying cancer samples and a Tissue of Origin Identification (TOOAI) model for distinguishing specific cancer types. These models are applied to test samples and provide a score based on tissue of origin probability. The present invention aims to revolutionize early cancer detection through advanced analytical and machine learning techniques.

A method for detecting cancer or predicting a cancer prognosis is provided. The method involves the detection of Tetraspanin 10 in a sample of bodily fluid from a subject.

The invention relates to the technical field of esophageal cancer early screening, in particular to an esophageal cancer early screening system and screening method using fluorescence-labeled exosome protein. Comprising the following steps: acquiring and pre-treating a patient body fluid sample to obtain a pre-treated body fluid sample; performing exosome separation on the pretreated body fluid sample to obtain an exosome suspension; carrying out specific labeling on the exosome suspension by using a fluorescent nanoprobe to obtain a fluorescently labeled exosome solution; performing fluorescence signal detection on the exosome solution subjected to fluorescence labeling, and obtaining fluorescence intensity data and multispectral fluorescence image data based on a fluorescence signal; based on the fluorescence intensity data and the multispectral fluorescence image data, in combination with clinical data of a patient, intelligent comprehensive analysis is carried out, and a screening result is obtained. The technical problems that in early screening of esophageal cancer, the screening sensitivity and accuracy are low, and data analysis is inaccurate are solved.

This invention discloses a method and system for assessing tumor content in liquid biopsies. The method performs quality control on high-throughput sequencing data from body fluid samples, filtering germline variations, clonal hematopoietic-related variations, and sequencing errors to obtain copy number variation (CNV) information and somatic mutation characteristic information. A weighted mean squared error loss function is constructed based on the CNV information, and the tumor content is solved using a constrained gradient descent method. When the CNV signal does not meet preset judgment conditions, the system switches to the mutation characteristic module, constructing a negative log-likelihood function based on a binomial distribution based on the principal clonal cluster, and solving for the tumor content through iterative optimization. In extreme cases, a backoff mechanism is triggered. This invention combines the stability of CNV at high tumor content with the sensitivity of mutational VAF at low content, achieving adaptive assessment from low to high tumor content.

The invention relates to new chemical compounds and combinations of chemical compounds, for medical use, more specifically for cancer diagnosis, in particular for the detection of activity specific for pancreatic cancer and in the diagnosis of pancreatic cancer. The invention relates also to an in vitro method for the detection of enzymatic activity present in an individual's body fluid sample, using such a compound or combination. The invention further relates to an in vitro method for the diagnosis of pancreatic cancer, using such a compound or combination, a kit comprising such a compound or combination, and the use of such a compound or combination for detecting enzymatic activity specific for pancreatic cancer and the use of such a compound or combination for the diagnosis of pancreatic cancer. The invention relates furthermore to such a compound or combination of compounds for use as a diagnostic marker for pancreatic cancer, and a method for the treatment of pancreatic cancer comprising the step of carrying out the method for the diagnosis of pancreatic cancer as defined above using such a compound or combination.

The present invention relates to a body fluid detection rod, comprising: a handle part made into a shape that can be gripped by a user; and a collection part including one collection surface inserted into the insertion opening of the chamber to supply the collected body fluid sample to the internal space of the chamber in a state in which the body fluid sample is collected, and one contact surface at least a part of which is connected to the handle part.

Provided is a biomarker for clonal hematopoiesis. PYY, LEP, SCN3A, FCGR2A, CYTH3, CD8A, TK1, GBP6, DSC2, GP5, IL17D, CD244, SLC4A1, BGN, APOA4, and MMP7 in a body fluid sample.

The invention provides methods for assessing immune system function and status based on cellular analysis. Methods of the present invention involve obtaining mass properties of immune cells collected in a tissue or body fluid sample from a subject. Such mass properties may include the mass of one or more immune cells and / or changes in mass of such immune cells over a period of time. Such data is then used for determining a status of the subject's immune response, and subsequent diagnosis and treatment of an infection or immunological disease or dysfunction.

1. The name of the design product: microorganism culture monitor. 2. The use of the design product: for culturing, detecting aerobic bacteria, anaerobic bacteria, fungi and mycobacteria in blood and body fluid samples. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.